Metabolic deterioration of the sedentary control group in clinical trials

被引:7
|
作者
Patel, Mahesh J. [1 ]
Slentz, Cris A. [1 ]
Kraus, William E. [1 ]
机构
[1] Duke Univ, Med Ctr, Div Cardiovasc Med, Durham, NC 27710 USA
关键词
physical inactivity; DENSITY-LIPOPROTEIN-CHOLESTEROL; RISK REDUCTION INTERVENTION; EXERCISE TRAINING AMOUNT; CORONARY-HEART-DISEASE; ALL-CAUSE MORTALITY; PHYSICAL-ACTIVITY; SKELETAL-MUSCLE; VISCERAL FAT; BODY-WEIGHT; INTENSITY;
D O I
10.1152/japplphysiol.00421.2011
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Patel MJ, Slentz CA, Kraus WE. Metabolic deterioration of the sedentary control group in clinical trials. J Appl Physiol 111: 1211-1217, 2011. First published July 21, 2011; doi:10.1152/japplphysiol.00421.2011.-Randomized clinical trials of exercise training regimens in sedentary individuals have provided a mechanistic understanding of the long-term health benefits and consequences of physical activity and inactivity. The sedentary control periods from these trials have provided evidence of the progressive metabolic deterioration that results from as little as 4-6 mo of continuing a physically inactive lifestyle. These clinical trials have also demonstrated that only a modest amount of physical activity is required to prevent this metabolic deterioration, and this amount of physical activity is consistent with current physical activity recommendations (150 min/wk of moderate intensity physical activity). These recommendations have been issued to the general population for a vast array of health benefits. While greater adherence to these recommendations should result in substantial improvements in the health of the population, these recommendations still remain inadequate for many individuals. An individual's physical activity requirements are influenced by such factors as an individual's diet, nonexercise physical activity patterns, genetic profile, and medications. Improving the understanding of how these factors influence an individual's physical activity requirements will help advance the field and help move the field toward the development of more personalized physical activity recommendations.
引用
收藏
页码:1211 / 1217
页数:7
相关论文
共 50 条
  • [21] The NIDA Methamphetamine Clinical Trials Group: A strategy to increase clinical trials research capacity
    Elkashef, Ahmed
    Rawson, Richard A.
    Smith, Edwina
    Pearce, Valerie
    Flammino, Frank
    Campbell, Jan
    Donovick, Roger
    Gorodetzky, Charles
    Haning, William
    Mawhinney, Joseph
    McCann, Michael
    Weis, Dennis
    Williams, Lorie
    Ling, Walter
    Vocci, Frank
    ADDICTION, 2007, 102 : 107 - 113
  • [22] Completion and publication of clinical trials in a cooperative group: a cohort study of trials of the Swiss Group for Clinical Cancer Research (SAKK)
    Hayoz, Stefanie
    Kasenda, Benjamin
    Schenker, Annina Lea
    Kopp, Christoph
    Schar, Sami
    Thurlimann, Beat
    von Moos, Roger
    Pless, Miklos
    BMJ OPEN, 2023, 13 (04):
  • [23] Clinical trials in group 3 pulmonary hypertension
    Harder, Eileen M.
    Waxman, Aaron B.
    CURRENT OPINION IN PULMONARY MEDICINE, 2020, 26 (05) : 391 - 396
  • [24] ANALYSES OF GROUP SEQUENTIAL CLINICAL-TRIALS
    KOEPCKE, W
    CONTROLLED CLINICAL TRIALS, 1989, 10 (04): : S222 - S230
  • [25] The design and analysis of clinical trials for group therapies
    Roberts, C
    CONTROLLED CLINICAL TRIALS, 2003, 24 : 72S - 72S
  • [26] Managing accrual in cooperative group clinical trials
    Demmy, TL
    Yasko, JM
    Collyar, DE
    Katz, ML
    Krasnov, CL
    Borwhat, MJ
    Battershell, A
    George, SL
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) : 2997 - 3002
  • [27] Optimal designs for group sequential clinical trials
    Chang, MN
    COMMUNICATIONS IN STATISTICS-THEORY AND METHODS, 1996, 25 (02) : 361 - 379
  • [28] Importance of body weight control on metabolic deterioration of type 2 diabetes
    Salvador, J.
    Escalada, J.
    AVANCES EN DIABETOLOGIA, 2010, 26 (03): : 151 - 155
  • [29] DESIGNS OF CLINICAL-TRIALS - ACTIVE CONTROL (EQUIVALENCE) TRIALS - ACTIVE CONTROL EQUIVALENCE TRIALS
    COOPER, EC
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1990, 3 : S77 - S81
  • [30] LUTEAL PHASE (LP) METABOLIC DETERIORATION IN DIABETES IS MASKED BY POOR CONTROL
    PRIOR, JC
    HUNT, JA
    ALOJADO, N
    REIMER, L
    SCHECHTER, M
    CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, 1985, 8 (03): : A71 - A71